Recently, the world's first proton pump inhibitor, the lansoprazole orally disintegrating tablet (Putoping), which is rapidly disintegrating in the oral cavity, was listed in Tianjin, Beijing, Shanghai, Nanjing and Hangzhou.
Lansoprazole orally disintegrating tablets will provide a good treatment for patients with acid-related diseases such as peptic ulcer and reflux esophagitis who have difficulty in taking dysphagia and other medications. It disintegrates into a myriad of enteric coated microparticles in 30 seconds. These microparticles are only about 300 microns in diameter and are 1/3 the diameter of common enteric coated microparticles. Each particle consists of a 7-layer structure that resists the squeezing caused by gastric peristalsis, thus ensuring that the efficacy is not affected. This unique dosage form allows for a variety of medications, in addition to traditional direct water delivery, it can also be taken by direct oral and nasogastric administration.
Located in Osaka, Japan, Takeda is a research-based global company that specializes in the pharmaceutical industry. As one of Japan's largest pharmaceutical companies and one of the world's leading companies in the industry, Takeda is committed to improving people's health and medical advancement by developing first-class medicines. According to Tianjin Takeda Pharmaceutical Co., the drug was listed in the United Kingdom and the United States in March 2002 and July 2003, respectively.
Lansoprazole orally disintegrating tablets will provide a good treatment for patients with acid-related diseases such as peptic ulcer and reflux esophagitis who have difficulty in taking dysphagia and other medications. It disintegrates into a myriad of enteric coated microparticles in 30 seconds. These microparticles are only about 300 microns in diameter and are 1/3 the diameter of common enteric coated microparticles. Each particle consists of a 7-layer structure that resists the squeezing caused by gastric peristalsis, thus ensuring that the efficacy is not affected. This unique dosage form allows for a variety of medications, in addition to traditional direct water delivery, it can also be taken by direct oral and nasogastric administration.
Located in Osaka, Japan, Takeda is a research-based global company that specializes in the pharmaceutical industry. As one of Japan's largest pharmaceutical companies and one of the world's leading companies in the industry, Takeda is committed to improving people's health and medical advancement by developing first-class medicines. According to Tianjin Takeda Pharmaceutical Co., the drug was listed in the United Kingdom and the United States in March 2002 and July 2003, respectively.
tbbs rubber accelerator,zdbc rubber accelerator,tmtm rubber accelerator,mbts rubber accelerator,thiuram rubber accelerator
GuangDong DuBa New Material Technology Co.,LTD , https://www.gddubachem.com